08/11/2022 | Press release | Distributed by Public on 08/11/2022 18:43
As filed with the Securities and Exchange Commission on August 11, 2022.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Palisade Bio, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 2834 | 52-2007292 | ||
(State or Other Jurisdiction of Incorporation or Organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
Palisade Bio, Inc.
7750 El Camino Real, Suite 5200
Carlsbad, CA 92009
(858) 704-4900
(Address, including zip code, and telephone number, including area code of registrant's principal executive offices)
Thomas Hallam, Ph.D., Chief Executive Officer
Palisade Bio, Inc.
7750 El Camino Real, Suite 5200
Carlsbad, CA 92009
(858) 704-4900
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Karen Deschaine, Esq. | Michael F. Nertney | |
Cooley LLP | Ellenoff Grossman & Schole LLP | |
4401 Eastgate Mall | 1345 Avenue of the Americas, 11th Floor | |
San Diego, California 92121 | New York, New York 10105 | |
(858) 550-6000 | (212) 370-1300 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-265769)
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
This registration statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This Registration Statement is being filed pursuant to Rule 462(b) as promulgated under the Securities Act of 1933, as amended, and includes the registration statement facing page, this page, the signature page, an exhibit index and the required opinion and consents solely to register up to an aggregate of $7,245,100 in (i) additional Class A Units, with each Class A Unit consisting of one share of our common stock, par value $0.01 per share (the "common stock") together with warrants with a term of one year, or Series 1 warrants, to purchase one share of common stock and warrants with a term of five years, or Series 2 warrants, to purchase one share of common stock (together with the shares of common stock underlying such warrants, the "Class A Unit"), (ii) additional Class B Units, with each Class B Unit consisting of one share of the Company's Series B Preferred Stock, par value $0.01 per share (the "Series B Preferred Stock") together with Series 1 warrants to purchase a number of shares of common stock equal to $1,000 divided by the conversion price of the Series B Preferred Stock, and Series 2 warrants to purchase a number of shares of common stock equal to $1,000 divided by the conversion price of the Series B Preferred Stock (together with the shares of common stock underlying such shares of Series B Preferred Stock and such warrants, the "Class B Units"), (iii) Representative Warrant to purchase shares of common stock; and (iv) shares of common stock underlying the Representative Warrant. The contents of the Registration Statement on Form S-1 (Registration No. 333-265769), as amended, including the exhibits and power of attorney thereto, which was declared effective by the Securities and Exchange Commission on August 11, 2022, are incorporated by reference in this Registration Statement.
The required opinions and consents are listed on the Exhibit Index attached hereto and are filed herewith.
EXHIBIT INDEX
Exhibit Number |
Description of document | |
5.1 | Opinion of Cooley LLP. | |
23.1 | Consent of BDO USA LLP, Independent Registered Public Accounting Firm. | |
23.2 | Consent of Cooley LLP (included in Exhibit 5.1). | |
24.1 | Power of Attorney (incorporated by reference to the signature page of the Prior Registration Statement on Form S-1 (File No. 333-265769), filed with the Securities and Exchange Commission on June 22, 2022 and incorporated herein by reference). | |
107 | Filing Fee Table. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California on August 11, 2022.
Palisade Bio, Inc. | ||
By: |
/s/ Thomas M. Hallam, Ph.D. |
|
Thomas M. Hallam, Ph.D. | ||
Chief Executive Officer |
POWER OF ATTORNEY
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.
Signature |
Title |
Date |
||
/s/ Thomas M. Hallam, Ph.D. | Chief Executive Officer and Director | August 11, 2022 | ||
Thomas M. Hallam, Ph.D. | (Principal Executive Officer) | |||
/s/ J. D. Finley | Chief Financial Officer | August 11, 2022 | ||
J.D. Finley | (Principal Financial Officer and Principal Accounting Officer) | |||
* | Chairman of the Board of Directors | August 11, 2022 | ||
James R. Neal | ||||
* | Director | August 11, 2022 | ||
Cristina Csimma, Pharm.D. | ||||
* | Director | August 11, 2022 | ||
Stephanie Diaz | ||||
* | Director | August 11, 2022 | ||
Mary Ann Gray, Ph.D | ||||
* | Director | August 11, 2022 | ||
Robert J. Trenschel, D.O. | ||||
* | Director | August 11, 2022 | ||
Binxian Wei | ||||
* | Director | August 11, 2022 | ||
Donald A. Williams |
*By: |
/s/ J.D. Finley |
|
J.D. Finley | ||
Attorney-in-Fact |